ImmunityBio ISPOR data show why NMIBC treatment choices are becoming harder to standardize
Bladder cancer care is shifting from survival alone to treatment trade-offs. ImmunityBio’s NMIBC survey shows why preference now matters.
Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate
Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.
Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise
ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.
Why ImmunityBio’s Japan BCG Laboratory agreement matters beyond bladder cancer supply
A bladder cancer supply crisis meets fresh Phase III data. ImmunityBio’s Tokyo BCG deal could test how flexible U.S. regulators are willing to be.
Macau clears ImmunityBio’s ANKTIVA for BCG-unresponsive NMIBC, opening Asia market amid commercialization test
ImmunityBio’s first Asia approval for ANKTIVA in BCG-unresponsive bladder cancer: what the Macau clearance means for its global strategy. Read the analysis.
ImmunityBio resubmits FDA application for ANKTIVA in bladder cancer after agency requests updated efficacy data
ImmunityBio has resubmitted its supplemental biologics license application to the U.S. Food and Drug Administration for ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guerin for BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, after the agency requested updated long-term efficacy data in March 2026. The resubmission follows a regulatory exchange that began in January […]
Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care
ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.
How ImmunityBio’s ANKTIVA combo is challenging glioblastoma’s immune collapse model
New Phase 2 data suggest ImmunityBio’s ANKTIVA plus CAR-NK combo could restore immune competence in glioblastoma. Find out why it matters.
ImmunityBio’s CAR-NK cell therapy achieves 15-month remission in Waldenström lymphoma
Find out how ImmunityBio’s CD19 CAR-NK cell therapy may change treatment for Waldenström lymphoma with durable responses and no chemotherapy.
Saudi FDA approves ImmunityBio’s ANKTIVA in NSCLC: What this means for immunotherapy 2.0
Find out how ImmunityBio’s subcutaneous immunotherapy ANKTIVA secured Saudi approval for NSCLC and what it means for global immuno-oncology.